| 臺大學術典藏 |
2021-02-18T01:45:21Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chiun Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Chiun Hsu; Cheng A.-L.; Lee R.-C.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.;Yang T.-S.;Yen C.-J.;Cheng R.;Liu J.;Chiun Hsu; Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.;Chen M.-H.;Yang S.-H.;Chiun Hsu;Yen C.-J.;Tsou H.-H.;Su Y.-Y.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Chen M.-H.; Yang S.-H.; Chiun Hsu; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-18T09:11:58Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
YI-PING HUNG; YU-YUN SHAO; Chiun Hsu; CHIH-HUNG HSU; Lee, Jan Mou; Yang, Muh Hwa; Chao, Yee |
| 臺大學術典藏 |
2021 |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2020-08-14T01:27:01Z |
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
|
Ou, Da-Liang;Lin, Yu-Yang;Hsu, Chia-Lang;Lin, Yin-Yao;Chen, Chia-Wei;Yu, Jhang-Sian;Shi-Chuen Miaw;Hsu, Ping-Ning;Cheng, Ann-Lii;Chiun Hsu; Ou, Da-Liang; Lin, Yu-Yang; Hsu, Chia-Lang; Lin, Yin-Yao; Chen, Chia-Wei; Yu, Jhang-Sian; SHI-CHUEN MIAW; Hsu, Ping-Ning; Cheng, Ann-Lii; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:33Z |
Surgical resection for recurrent hepatocellular carcinoma: Prognosis and analysis of risk factors
|
Hu R.-H.;Lee P.-H.;Yu S.-C.;Dai H.-C.;Sheu J.-C.;Lai M.-Y.;Chiun Hsu;Chen D.-S.; Hu R.-H.; Lee P.-H.; Yu S.-C.; Dai H.-C.; Sheu J.-C.; Lai M.-Y.; Chiun Hsu; Chen D.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response?
|
Chiun Hsu;Chen C.-L.;Chen L.-T.;Liu H.-T.;Chen Y.-C.;Jan C.-M.;Liu C.-S.;Cheng A.-L.; Chiun Hsu; Chen C.-L.; Chen L.-T.; Liu H.-T.; Chen Y.-C.; Jan C.-M.; Liu C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach
|
Cheng A.-L.; Chen Y.-C.; Chen L.-T.; Chiang I.-P.; Chen C.-L.; Chiun Hsu; Liu H.-T.; Liu H.-T.;Chiun Hsu;Chen C.-L.;Chiang I.-P.;Chen L.-T.;Chen Y.-C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
|
Chiun Hsu;Lin M.-T.;Tang J.-L.;Tien H.-F.;Wang C.-H.;Chen Y.-C.; Chiun Hsu; Lin M.-T.; Tang J.-L.; Tien H.-F.; Wang C.-H.; Chen Y.-C. |
